TY - JOUR
T1 - Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase
T2 - an Italian multicenter study over two years in real life
AU - Santoleri, Fiorenzo
AU - Ranucci, Elena
AU - La Barba, Gaetano
AU - Colasanto, Irene
AU - Scaldaferri, Matilde
AU - Cattel, Francesco
AU - Federici, Francesca
AU - Rossi, Chiara
AU - Di Biagio, Katiuscia
AU - Scortechini, Anna Rita
AU - Musicco, Felice
AU - Torquati, Giancarlo
AU - Frazzetto, Angela
AU - Vozza, Antonietta
AU - de Rosa, Caterina
AU - Lanzillo, Rosaria
AU - Monteverde, Maria
AU - Luciano, Luigia
AU - Pane, Fabrizio
AU - Pasquazi, Arianna
AU - Celeste, Maria Grazia
AU - Cantonetti, Maria
AU - Franceschini, Luca
AU - Rizzo, Manuela
AU - Costantini, Alberto
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Background: The use of dasatinib and nilotinib in the treatment of patients with chronic myeloid leukemia represents a valid therapeutic option for patients resistant or intolerant to imatinib. In this multicentre study, adherence, persistence and efficacy in real life over two years of treatment were evaluated. Materials and methods: Adherence to treatment was calculated as the ratio between the dose received and the prescribed dose. The dose received was calculated using pharmacy refill data. The persistence with treatment was calculated as the difference between the end and the beginning of the treatment. Efficacy was assigned as Progression-Free Survival (PFS) and Events-Free Survival (EFS) and represented through the Kaplan-Meier curve. Results: The number of patients analysed was 117, 70 treated with dasatinib and 47 with nilotinib. Adherence to treatment for dasatinib and nilotinib at two years was 0.91 and 0.82 respectively. Persistence at two years was 77% while the PFS was 92% for both drugs in the study. Conclusion: Adherence to the treatment calculated over two years showed a superiority of dasatinib over nilotinib. Nevertheless, the efficacy in terms of PFS and EFS is superimposable between the two drugs in the study.
AB - Background: The use of dasatinib and nilotinib in the treatment of patients with chronic myeloid leukemia represents a valid therapeutic option for patients resistant or intolerant to imatinib. In this multicentre study, adherence, persistence and efficacy in real life over two years of treatment were evaluated. Materials and methods: Adherence to treatment was calculated as the ratio between the dose received and the prescribed dose. The dose received was calculated using pharmacy refill data. The persistence with treatment was calculated as the difference between the end and the beginning of the treatment. Efficacy was assigned as Progression-Free Survival (PFS) and Events-Free Survival (EFS) and represented through the Kaplan-Meier curve. Results: The number of patients analysed was 117, 70 treated with dasatinib and 47 with nilotinib. Adherence to treatment for dasatinib and nilotinib at two years was 0.91 and 0.82 respectively. Persistence at two years was 77% while the PFS was 92% for both drugs in the study. Conclusion: Adherence to the treatment calculated over two years showed a superiority of dasatinib over nilotinib. Nevertheless, the efficacy in terms of PFS and EFS is superimposable between the two drugs in the study.
KW - chronic myeloid leukaemia
KW - Dasatinib
KW - drug used study
KW - effectiveness
KW - medication adherence
KW - nilotinib
KW - persistence
UR - http://www.scopus.com/inward/record.url?scp=85100156068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100156068&partnerID=8YFLogxK
U2 - 10.1080/03007995.2021.1876006
DO - 10.1080/03007995.2021.1876006
M3 - Article
AN - SCOPUS:85100156068
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
SN - 0300-7995
ER -